Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00804596 · ClinicalTrials.gov registry record · NA

Evaluation of Labeling Comprehension and Performance of a New Blood Glucose Meter System

A NA study of Diabetes, sponsored by Ascensia Diabetes Care.

Completed
Registry status
NA
Development phase
74
Enrollment target
1
Study location

NCT00804596: Completed NA study of Diabetes, sponsored by Ascensia Diabetes Care.

NCT00804596 is a NA study of Diabetes that has completed, run by Ascensia Diabetes Care. The registered enrollment target is 74 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00804596, a NA study of Diabetes, has completed, sponsored by Ascensia Diabetes Care.

COMPLETED
Registry status
NA
Development phase
74 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study was to evaluate the acceptability of product user guides for untrained subjects and to evaluate the performance of the system with lay users and healthcare providers (HCPs).

Primary Outcome

Study staff rated participants on their success at performing Blood Glucose (BG) testing and other system features after subjects read product labeling. The rating scale was: 1. Successful in performing tasks correctly without assistance 2. Successful after being referred to user instructions 3. Successful after verbal assistance or review of part of user instructions (Similar to review of a specific function during a Customer Service call.) 4. Unsuccessful (Incorrectly performed part of the te

Conditions Studied

Interventions

  • DEVICE Apollo Blood Glucose Monitoring System

Study Locations (1)

Minnesota

  • International Diabetes Center - Minneapolis

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2008-12
Est. Completion 2009-01
Phase NA
Ascensia Diabetes Care

42 total trials

What the finished NCT00804596 record still lists

NCT00804596 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Apollo Blood Glucose Monitoring System is the first listed.

NCT00804596 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT00804596 about?

NCT00804596 is a clinical study titled "Evaluation of Labeling Comprehension and Performance of a New Blood Glucose Meter System". The purpose of the study was to evaluate the acceptability of product user guides for untrained subjects and to evaluate the performance of the system with lay users and healthcare providers (HCPs).

What is the current status of trial NCT00804596?

This trial is currently completed. It is a NA study. The enrollment target is 74 participants. The study started on 2008-12. Estimated completion is 2009-01.

What conditions does trial NCT00804596 study?

This clinical trial studies the following conditions: Diabetes.

What interventions are being tested in trial NCT00804596?

The interventions under investigation include: Apollo Blood Glucose Monitoring System (DEVICE).

Who is sponsoring clinical trial NCT00804596?

This trial is sponsored by Ascensia Diabetes Care, which has 42 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00804596 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00804596's enrollment target sits among peer trials

74 220th of 338 higher than 119 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03422731 · 74 participants · Early Phase 1

    Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

  • NCT03804853 · 74 participants · NA

    Rehabilitation Following Reverse Total Shoulder Arthroplasty

  • NCT04065776 · 74 participants · NA

    Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

  • NCT04771156 · 74 participants · Phase 4

    Ketorolac in Palatoplasty

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00804596, the US trial registry maintained by the National Library of Medicine. NCT00804596 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.